In:
International Journal of Cancer, Wiley, Vol. 136, No. 6 ( 2015-03-15)
Kurzfassung:
What's new? Novel agents have been introduced to treat patients with metastatic castrate‐resistant prostate cancer (mCRPC). Among those are cabazitaxel, a second‐generation taxane, and abiraterone, which inhibits testosterone biosynthesis through blockade of cytochrome p450 c17. This retrospective study evaluated clinical outcome of cabazitaxel and abiraterone sequential treatment in docetaxel‐treated mCRPC patients. Patient survival did not differ significantly based on treatment sequence. The antitumor efficacy of cabazitaxel was lower after abiraterone, but prior treatment with one agent did not preclude a response to the other. Toxicity of the two drugs differed, with cabazitaxel having greater potential for severe toxicity.
Materialart:
Online-Ressource
ISSN:
0020-7136
,
1097-0215
Sprache:
Englisch
Verlag:
Wiley
Publikationsdatum:
2015
ZDB Id:
218257-9
ZDB Id:
1474822-8
